ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
122.799,09
-1,60%
S&P 500
5.778,15
-1,22%
US Dollar vs BRL
6,23633
3,56%
Bitcoin
87.541,39
1,69%
Brent Oil
71,035
-0,51%
As Melhores Corretoras Online
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Apellis Pharmaceuticals Inc (APLS)

  7. Apellis Pharmaceuticals Inc (APLS) Notícias

APLS

Apellis Pharmaceuticals (APLS)

Apellis Pharmaceuticals Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:APLS
DataHoraFonteTítuloCódigoCompanhia
28/02/202509:22Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:APLSApellis Pharmaceuticals Inc
28/02/202509:05GlobeNewswire Inc.Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial ResultsNASDAQ:APLSApellis Pharmaceuticals Inc
24/02/202509:00GlobeNewswire Inc.Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care ConferenceNASDAQ:APLSApellis Pharmaceuticals Inc
20/02/202504:00GlobeNewswire Inc.Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGNNASDAQ:APLSApellis Pharmaceuticals Inc
14/02/202509:00GlobeNewswire Inc.Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial ResultsNASDAQ:APLSApellis Pharmaceuticals Inc
12/02/202515:59Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:APLSApellis Pharmaceuticals Inc
11/02/202517:13Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:APLSApellis Pharmaceuticals Inc
04/02/202518:05GlobeNewswire Inc.Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:APLSApellis Pharmaceuticals Inc
27/01/202518:00GlobeNewswire Inc.Apellis Receives Approval of SYFOVRE® (pegcetacoplan) in Australia for Geographic Atrophy (GA)NASDAQ:APLSApellis Pharmaceuticals Inc
13/01/202511:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APLSApellis Pharmaceuticals Inc
13/01/202511:00GlobeNewswire Inc.Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:APLSApellis Pharmaceuticals Inc
10/01/202519:38Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:APLSApellis Pharmaceuticals Inc
10/01/202509:00GlobeNewswire Inc.Apellis Announces Keli Walbert to Join the Board of DirectorsNASDAQ:APLSApellis Pharmaceuticals Inc
06/01/202509:00GlobeNewswire Inc.Apellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:APLSApellis Pharmaceuticals Inc
27/11/202409:00GlobeNewswire Inc.Apellis Pharmaceuticals to Present at Upcoming Investor ConferencesNASDAQ:APLSApellis Pharmaceuticals Inc
22/11/202418:16Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:APLSApellis Pharmaceuticals Inc
22/11/202410:47Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:APLSApellis Pharmaceuticals Inc
12/11/202409:00GlobeNewswire Inc.Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare ConferenceNASDAQ:APLSApellis Pharmaceuticals Inc
05/11/202409:05GlobeNewswire Inc.Apellis Pharmaceuticals Reports Third Quarter 2024 Financial ResultsNASDAQ:APLSApellis Pharmaceuticals Inc
05/11/202408:57Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:APLSApellis Pharmaceuticals Inc
05/11/202408:46IH Market NewsU.S. Index Futures Rise as Election Looms; Oil and Gold Prices SteadyNASDAQ:APLSApellis Pharmaceuticals Inc
26/10/202415:00GlobeNewswire Inc.Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGNNASDAQ:APLSApellis Pharmaceuticals Inc
22/10/202408:00GlobeNewswire Inc.Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial ResultsNASDAQ:APLSApellis Pharmaceuticals Inc
16/10/202408:00GlobeNewswire Inc.Apellis Announces Oral Presentation at American Society of Nephrology (ASN) Kidney Week on Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGNNASDAQ:APLSApellis Pharmaceuticals Inc
25/09/202408:00GlobeNewswire Inc.Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology DayNASDAQ:APLSApellis Pharmaceuticals Inc
20/09/202406:00GlobeNewswire Inc.Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Following Re-ExaminationNASDAQ:APLSApellis Pharmaceuticals Inc
08/08/202408:32PR Newswire (US)Sobi and Apellis announce positive topline results from phase 3 VALIANT study of pegcetacoplan in C3G and primary IC-MPGNNASDAQ:APLSApellis Pharmaceuticals Inc
08/08/202408:00GlobeNewswire Inc.Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGNNASDAQ:APLSApellis Pharmaceuticals Inc
01/08/202408:05GlobeNewswire Inc.Apellis Pharmaceuticals Reports Second Quarter 2024 Financial ResultsNASDAQ:APLSApellis Pharmaceuticals Inc
18/07/202420:39PR Newswire (US)Kuehn Law Encourages Investors of Apellis Pharmaceuticals, Inc. to Contact Law FirmNASDAQ:APLSApellis Pharmaceuticals Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:APLS

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
COGN3
COGNA ON
BOV
PRIO3
PETRORIO ON
BOV
TELB4
TELEBRAS PN
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios